

# CITATION REPORT

List of articles citing

## Direct Inhibition of MmpL3 by Novel Antitubercular Compou

DOI: 10.1021/acsinfecdis.9b00048  
ACS Infectious Diseases, 2019, 5, 1001-1012.

**Source:** <https://exaly.com/paper-pdf/73403349/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
60	Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition.		
59	Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	18
58	Metabolism. <i>Microbiology Spectrum</i> , <b>2019</b> , 7,	8.9	7
57	Synthesis of New Indole and Adamantane Amido Derivatives with Pharmacological Interest. <i>ChemistrySelect</i> , <b>2019</b> , 4, 8727-8730	1.8	4
56	The MmpL3 interactome reveals a complex crosstalk between cell envelope biosynthesis and cell elongation and division in mycobacteria. <i>Scientific Reports</i> , <b>2019</b> , 9, 10728	4.9	19
55	Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in <i>Mycobacterium tuberculosis</i> . <i>Nature Communications</i> , <b>2019</b> , 10, 2928	17.4	45
54	A piperidinol-containing molecule is active against by inhibiting the mycolic acid flippase activity of MmpL3. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 17512-17523	5.4	21
53	Synthesis, biology, computational studies and in vitro controlled release of new isoniazid-based adamantane derivatives. <i>Future Medicinal Chemistry</i> , <b>2019</b> , 11, 2779-2802	4.1	3
52	<i>Mycobacterium tuberculosis</i> Metabolism. <b>2019</b> , 1107-1128		
51	Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in. <i>ACS Infectious Diseases</i> , <b>2020</b> , 6, 324-337	5.5	25
50	Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
49	Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 582416	5.9	2
48	MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
47	Multiple Mutations in <i>Mycobacterium tuberculosis</i> MmpL3 Increase Resistance to MmpL3 Inhibitors. <i>MSphere</i> , <b>2020</b> , 5,	5	5
46	MtrP, a putative methyltransferase in <i>Corynebacteria</i> , is required for optimal membrane transport of trehalose mycolates. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 6108-6119	5.4	6
45	MmpL3 inhibitors as antituberculosis drugs. <i>European Journal of Medicinal Chemistry</i> , <b>2020</b> , 200, 112390	6.8	9
44	Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition. <i>ACS Infectious Diseases</i> , <b>2020</b> , 6, 1882-1893	5.5	4

43	Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis. <i>Molecules</i> , <b>2020</b> , 25,	4.8	10
42	Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. <i>Applied Sciences (Switzerland)</i> , <b>2020</b> , 10, 623	2.6	18
41	The quest for the holy grail: new antitubercular chemical entities, targets and strategies. <i>Drug Discovery Today</i> , <b>2020</b> , 25, 772-780	8.8	15
40	Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents. <i>RSC Advances</i> , <b>2020</b> , 10, 7523-7540	3.7	16
39	Transporters Involved in the Biogenesis and Functionalization of the Mycobacterial Cell Envelope. <i>Chemical Reviews</i> , <b>2021</b> , 121, 5124-5157	68.1	14
38	Amide-Amine Replacement in Indole-2-carboxamides Yields Potent Mycobactericidal Agents with Improved Water Solubility. <i>ACS Medicinal Chemistry Letters</i> , <b>2021</b> , 12, 704-712	4.3	3
37	Loperamide exerts a direct bactericidal effect against <i>M. tuberculosis</i> , <i>M. bovis</i> , <i>M. terrae</i> and <i>M. smegmatis</i> . <i>Letters in Applied Microbiology</i> , <b>2021</b> , 72, 351-356	2.9	1
36	Structural and Functional Diversity of Resistance-Nodulation-Cell Division Transporters. <i>Chemical Reviews</i> , <b>2021</b> , 121, 5378-5416	68.1	16
35	Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis. <i>Bioorganic Chemistry</i> , <b>2021</b> , 106, 104486	5.1	6
34	Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 141-152	5.5	3
33	Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of and paediatric brain tumour cells.. <i>RSC Advances</i> , <b>2021</b> , 11, 15497-15511	3.7	4
32	Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors. <i>Accounts of Chemical Research</i> , <b>2021</b> , 54, 930-939	24.3	4
31	The role of transport proteins in the production of microbial glycolipid biosurfactants. <i>Applied Microbiology and Biotechnology</i> , <b>2021</b> , 105, 1779-1793	5.7	5
30	Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. <i>Medicinal Research Reviews</i> , <b>2021</b> , 41, 2350-2387	14.4	12
29	Cryo-EM structure and resistance landscape of <i>M. tuberculosis</i> MmpL3: An emergent therapeutic target. <i>Structure</i> , <b>2021</b> , 29, 1182-1191.e4	5.2	6
28	Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis. <i>ChemMedChem</i> , <b>2021</b> , 16, 3136-3148	3.7	4
27	Mechanistic Duality of Bacterial Efflux Substrates and Inhibitors: Example of Simple Substituted Cinnamoyl and Naphthyl Amides. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 2650-2665	5.5	1
26	Identification of anti-mycobacterial agents against mmpL3: Virtual screening, ADMET analysis and MD simulations. <i>Journal of Molecular Structure</i> , <b>2021</b> , 1244, 130941	3.4	8

25	Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 611683	5.9	5
24	Targeting MmpL3 for anti-tuberculosis drug development. <i>Biochemical Society Transactions</i> , <b>2020</b> , 48, 1463-1472	5.1	5
23	Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450.		1
22	Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 197, 114906	6	0
21	Implications of Metabolic Adaptability on Drug Discovery and Development.. <i>ACS Infectious Diseases</i> , <b>2022</b> ,	5.5	0
20	2-Aminoimidazoles Inhibit Biofilms in a Zinc-Dependent Manner.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
19	Table_1.docx. <b>2020</b> ,		
18	Computational design of MmpL3 inhibitors for tuberculosis therapy.. <i>Molecular Diversity</i> , <b>2022</b> , 1	3.1	
17	Approaches for Targeting the Mycobactin Biosynthesis Pathway for Novel Anti-tubercular Drug Discovery: Where We Stand.. <i>Expert Opinion on Drug Discovery</i> , <b>2022</b> ,	6.2	1
16	Proton transfer activity of the reconstituted Mycobacterium tuberculosis MmpL3 is modulated by substrate mimics and inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	0
15	The driving force for mycolic acid export by mycobacterial MmpL3 is proton translocation. <b>2022</b> , 119,		
14	Analysis of Orthogonal Efflux and Permeation Properties of Compounds Leads to the Discovery of New Efflux Pump Inhibitors.		0
13	Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening. <b>2022</b> , 12,		0
12	A HydrazineHydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3. <b>2022</b> , 27, 7130		1
11	Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines TargetingMycobacterium tuberculosis.		0
10	Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3. <b>2023</b> , 138, 102288		0
9	Repurposing Vanoxerine as a new antimycobacterial drug and its impact on the mycobacterial membrane.		0
8	Conformational restriction shapes inhibition of a multidrug efflux adaptor protein.		0

7	Structural Determinants of Indole-2-carboxamides: Identification of Lead Acetamides with Pan Antimycobacterial Activity.	0
6	Mycobacterium smegmatis: The Vanguard of Mycobacterial Research.	2
5	Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against Mycobacterium abscessus and Malaria Parasites. <b>2023</b> , 9, 342-364	0
4	Vanoxerine kills mycobacteria through membrane depolarization and efflux inhibition. 14,	0
3	Molecular Mechanisms of MmpL3 Function and Inhibition.	0
2	Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. <b>2023</b> , 24, 5202	0
1	Design, synthesis, and biological evaluation of 1,2,4-triazole derivatives as potent antitubercular agents. <b>2023</b> , 108464	0